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Low-income countries are facing a surge in the burden of 
cardiovascular diseases (CVDs) which, along with other 
non-communicable diseases, are overtaking infectious 
diseases as top killers in these settings (1,2). Rural 
populations are particularly vulnerable owing to their very 
limited access to either qualified health professionals or 
effective interventions for CVDs, notably diagnostic tools 
and essential medicines (3,4). Effective delivery of adequate 
cardiovascular care to rural populations in sub-Saharan 
Africa, South and East Asia should therefore be a priority 
for global health programs.
As acknowledged by the World Health Organization and 
increasingly by national health authorities, telemedicine is 
an important strategy to overcome the shortage of health 
professionals and improve delivery of health care to rural 
populations in low-to-middle-income countries (5). It has 
the potential to reduce socioeconomic disparities in the 
management of CVDs. Two years ago, we presented the 
Cardio-PadTM (Figure 1), a tele-cardiology device which 
enables to perform electrocardiograms (ECG) in remote 
underserved areas and transfer the test results wirelessly to 
specialist physicians who can interpret them and provide 
assistance for cases management (6). The Cardio-PadTM 
was designed and developed by Arthur Zang, a young 
Cameroon-based engineer, who received several awards 
including the 2014 Rolex Award for Enterprise (7) and 
the 2016 Africa Prize for engineering innovation from 
the Royal Academy of Engineering (8) for this invention 
recognized as the first medical computer tablet originating 
from Africa. In this paper, we present updates on the 
Cardio-PadTM initiative and some of its limitations and 
remaining challenges.
The technical features of the Cardio-PadTM have been 
previously described (6). In brief, the Cardio-PadTM is a 
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touchscreen tablet whose main internal components include 
a Dual Core processor, a Double Data Rate Random Access 
Memory (DDR RAM), an internal memory for data storage, 
a Global System for Mobile/General Packet Radio Services 
(GSM/GPRS) for data transmission, a SIM card connector, 
GPS, Bluetooth and Wi-Fi modules, a lithium battery 
and two USB ports. External components include ECG 
electrodes and cables, and a Bluetooth sensor box which 
detects and digitalizes the heart signals from the electrodes 
connected to the patient and afterwards transfers them to 
the Cardio-PadTM via Bluetooth. The Cardio-PadTM is a 
multifunction cardiograph with two main functionalities: 
first, through the CardioPadgraphTM program, it performs 
a 12-lead ECG displayed on the pad; secondly, it allows 
transfer of patients’ data via the mobile phone network 
using a SIM card, to a National Data Centre and then to 
a specialist who can interpret the data and assist in the 
diagnosis and management of patients. The Cardio-PadTM 
can also function as a scope as it is able to perform real-time 
monitoring and recording of the heart’s electrical activity 
using the CardioPadScopeTM program. In the Cardio-PadTM 
user guide V.1, it is claimed that the device can also perform 
real-time monitoring of vital parameters such as respiratory 
rate, blood pressure, temperature and oximetry. However, 
no accessories are provided in the Cardio-Pad kit for the 
recording of these parameters, and the procedure to use the 
scope function is not described.
Some improvements have been made on the prototype 
available in 2014. First, although the autonomy of the 
built-in battery has not been improved, a solar panel is 
now provided to charge the battery using solar energy, 
making it more suitable for use in remote villages where 
there is limited electricity supply. Second, the ECG 
displayed on the Cardio-PadTM can now be printed on 
an A4 paper compatible with all printers, and stored in 
patients’ folders. This is an interesting feature, especially 
for hospitals where patients’ medical information are not 
archived electronically. Third, according to the developer, 
the information recorded by a Cardio-PadTM can now be 
transferred not only to another Cardio-PadTM but also to 
any smartphone. Through a software that can be freely 
downloaded on the Cardio-PadTM website, the smartphone 
can receive signals from a Cardio-PadTM, treat them and 
generate ECG images in various formats including JPEG. 
Fourth, a wireless mouse and a keyboard are now provided 
as backup solutions in case of damaged touchscreen or for 
users less comfortable with it.
The commercialization of the Cardio-Pad started in 
early 2016. According to Himore Medical Equipments, 
the company which produces and commercializes the 
Cardio-PadTM, 300 pads have been produced and about 
50 have been sold to date. Most of the buyers were Non-
Governmental Organizations in Nepal, India, Comores 
Island and Gabon. The manufacturer assures that there 
is a close follow-up of the products delivered. Local 
partnerships to ensure maintenance are being put in place in 
high sales countries and there is even a possibility to replace 
dysfunctional pads.
Despite the rapid commercialization of the Cardio-
PadTM driven by the clear potential to help improve the 
care of patients with CVDs in remote underserved areas 
in low-to-middle-income countries, several questions 
remain unanswered, pertaining to its reliability and cost-
effectiveness as a public health intervention. Moreover, 
there is virtually no peer-reviewed publication to support 
the Cardio-PadTM in the competition with similar 
technologies and devices being developed worldwide. Below 
are some recommendations to be considered by Himore 
Medical Equipments in order to ensure the success of the 
Cardio-PadTM. 
First, there is a need to validate the Cardio-PadTM 
against standard ECG devices. This should ideally be done 
by assessing the performance of the device in a group of 
healthy volunteers and publishing the results in an academic 
peer-reviewed biomedical journal. The results should 
include measures of inter-observer and intra-observer 
agreement (9-11); error margins for each of the multiple 
ECG parameters; optimal operating conditions; and 
quantification of the effects of some ecological or patient-
related factors on the performance of the device, notably 
age, gender, body mass index, patient’s or examiner’s 
Figure 1 The Cardio-PadTM kit (From the Cardio-Pad user guide V.1).
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mobility during the recording, exercise, skin moisture, 
tobacco or caffeine consumption.
Second, the performance of the Cardio-PadTM for 
the diagnosis of cardiac diseases should be rigorously 
demonstrated in the pre-hospital and intra-hospital 
emergency settings where such device would be the most 
useful especially because it could facilitate the coordination 
of medical decisions and interventions by allowing 
simultaneous real-time visualization of patients’ ECGs by 
several teams. The priority should be given to some specific 
conditions such as myocardial infarction, conduction blocks, 
atrial fibrillation, dyskalemia, dyscalcemias, prolongation of 
the QT interval, and ventricular tachycardia. It should be 
noted that the Cardio-PadTM is actually lagging far behind 
its competitors. Indeed, several other portable electronic 
ECG devices are being developed all around the world with 
promising results (12-17). Therefore, the designers of the 
Cardio-PadTM should manage to catch up quickly in order 
to safeguard its competitiveness on the market. 
Third, it is advisable that medico-economic studies are 
conducted to quantify the clinical and economic benefits 
of using the Cardio-PadTM rather than current standard 
ECG devices even in rural settings with limited resources. 
Important items to consider include the average reduction 
of time to access meaningful information, the average gain 
of space allowed by cloud-based archiving, the average 
gain of time to diagnosis and treatment which converts 
into reduction of disability- and quality-adjusted life years 
(18-20), and the average reduction of the ECG cost due to 
savings on printing charges.
Fourth, while implementing technical and clinical 
validation studies, the staff at Himore Medical Equipments 
should also try to enhance the safety of patients’ data 
transfer and storage and incorporate new algorithms 
to assist users in the diagnostic process. Such advanced 
algorithms should be able to perform real-time analysis 
of the ECG and comparison with previous traces stored 
on the device or in the cloud. The safety of data transfer 
and storage is critical and should be taken seriously when 
contemplating the potential consequences of either the 
falsification or the deletion of patients’ medical information 
(21,22).
As a conclusion, we would like to congratulate and 
encourage Arthur Zang and his team for their invention 
and encourage them to keep aiming high in their quest 
of excellence. It is indeed a great achievement to have 
designed the Cardio-PadTM and constantly improved 
its functionalities over the years. We hope that the 
recommendations in this paper will help them take 
the necessary steps to ensure the worldwide success of 
the Cardio-PadTM especially in western countries were 
regulations on drugs and medical devices are more 
coercive and companies developing rival products are 
thriving. They should also realize that the implementation 
of these recommendations will request a diversification 
of the staff to include experts from various domains 
(cardiology, public health, biostatistics, data management, 
cybersecurity, economics, ethics, and law) and the initiation 
of international collaborations with various biomedical 
engineering institutes around the world. We would also 
like to take advantage of this tribune to raise the awareness 
of governments in low-to-middle income countries on the 
need to create regulatory boards that will closely monitor 
and guide the progressive introduction of new medical 
devices in their countries so as to minimize the health risks 
for their populations.
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